Abiomed's percutaneous heart pump clears Health Canada
Abiomed, a developer of heart support technologies, has received Health Canada approval to market the Impella cVAD device, a percutaneous Impella heart pump.
The Impella cVAD1 is designed to provide temporary circulatory support via a catheter-based pump that is inserted percutaneously. cVAD seeks to provide peak flow of approximately four liters of blood per minute, according to the Danvers, Mass.-based company.
The Impella cVAD is not currently cleared for sale or use in the U.S.
The Impella cVAD1 is designed to provide temporary circulatory support via a catheter-based pump that is inserted percutaneously. cVAD seeks to provide peak flow of approximately four liters of blood per minute, according to the Danvers, Mass.-based company.
The Impella cVAD is not currently cleared for sale or use in the U.S.